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Summary 
We here report hat c~t-acid glycoprotein, a typical acute phase protein, protects mice from lethal 
shock induced by tumor necrosis factor (TNF) or endotoxin. The protection is observed both 
in normal and in galactosamine-sensitized mice. Optimal desensitization requires at least 3 mg 
oq-add glycoprotein administered 2 h before the lethal challenge. Under these conditions, 
complete inhibition of all TNF-induced metabolic changes was observed: fall in body temperature, 
release of liver transaminases, nhanced dotting time, and mortality. The known phtelet aggregation- 
inhibitory activity of oq-acid glycoprotein provides a possible explanation for this protective 
capacity. 
T NF is considered to be the major mediator of both the shock-inducing and antitumor activities of endotoxins 
(1-3). But TNF, possibly in combination with IFN, also holds 
much promise for antitumor therapy, provided the induced 
systemic toxicity can be suppressed. Because of this, and in 
view of the key role played by TNF in septic shock, reduc- 
tion of the generalized, eleterious, inflammatory esponse 
is an important objective. We previously reported that a low 
dose of IL-1 or even TNF can protect mice against a subse- 
quent lethal challenge of TNF plus galactosamine (GaiN), 
LPS plus GAIN, or TNF alone, and that a factor produced 
by hepatocytes is responsible for this IL-1- or TNF-induced 
protection (4). 
In an attempt to identify this factor, we studied the effect 
of oq-acid glycoprotein (AGP), a typical acute phase protein 
in humans, rats, mice, and other species (5), the physiolog- 
ical role of which is still poorly understood. AGP is a highly 
glycosylated, polyanionic protein with an apparent Mr of 
"o40,000. It is induced mainly in hepatocytes by several 
cytokines, including TNF and IL-1, and by ghcocorticoids (6). 
In this report, we demonstrate hat AGP is able to very 
significantly protect animals from lethal shock induced by 
TNF or LPS. 
Materials and Methods 
Mice. Female C3H/HeJ mice (Charles River, Sulzfeld, Ger- 
many) and female C57B1/cnb (Studiecentrum voor Kernenergie, 
Mol, Belgium) were used at the age of 7-9 wk. The animals were 
kept in 12-h light/dark cycles in a temperature-controUed, air- 
conditioned room, and received food and water ad libitum. Rectal 
body temperatures were measured with an electronic thermom- 
eter (model 2001; Comark Electronics, Littlehampton, UK). 
Injections and Blood Collections. Intraperitoneal injections had 
a volume of 0.5 or I ml. The reagents were diluted in pyrogen-free 
PBS immediately before the injection. Some injections were intra- 
venous in a volume of 0.25 ml. Blood was collected by retroorbital 
bleeding under ether anesthesia and serum was prepared by incub- 
ating blood samples for 30 min at 37~ separation f the fibrin 
clot, and centrifugation (15 min; 16,000 g). For preparation of
plasma, 450 #I blood was collected by heart puncture with a sy- 
tinge containing 50 #1 sodium citrate (0.1 M). Platelet-ffee plasma 
was obtained by two consecutive c ntrifugations of 15 min at 
16,000 g. 
Reagents. GAIN, human AGP, rat AGP, bovine 00) AGP, human 
transferrin (TF), and BSA were obtained from Sigma Chemical 
Co. (St. Louis, MO). The bAGP preparations contained <1 ng en- 
dotoxin/mg protein and contained no biologically active IL-1, TNF, 
I1.,6, or in vitro TNF-inhibitory activity (as judged on L929 cells). 
bAGP was >99% pure as mentioned by the manufacturer. On a 
reducing, denaturing polyacrylamide gel, AGP appeared, asexpected, 
as two bands because of differential glycosylation (5); no con- 
taminating proteins were visible on such a gel. Esckerickia coli 0111:B4 
LPS and rabbit issue thromboplastin were from Difco Laborato- 
ries (Detroit, MI). Mouse AGP was prepared from turpentine-treated 
mice as described (7). Recombinant human (rh) TNF and recom- 
binant murine (rm) TNF were made in this laboratory, hTNF had 
asp act of 5 x 107 IU/mg and contained <0.11 ng endotoxin/mg 
protein; mTNF had asp act of 1.5 x 10 s IU/mg and contained 
<0.96 ng endotoxin/mg protein. Endotoxin levels were assessed 
by a chromogenic Limulus amoebocyte lysate assay (Coatest; 
KabiVitrum, Stockholm, Sweden). 
Quantification of Alanine Aminotransferase (ALT) and Aspartate 
Aminotransferase (AST), and Measurement of Modified Prothrombin Time 
(MPT). Serum ALT and AST were determined using a Hitachi 
analyzer and the ALT/AST kit of Sigma Chemical Co. MPT was 
measured as described (8): in baked, siliconized glass cuvettes, 
prewarmed at37~ 50/~1 plasma was added to 175/zl Tris-HC1 
(10 raM, pH 8, 100 mM NaC1) together with 25/zl of a 1/1,000 
dilution of rabbit issue thromboplastin. After incubation for 3 rain, 
coagulation was started at time zero by the addition of 250/~1 
Ca 2+ buffer (10 mM Ttis-HCl, pH 8, 80 mM NaC1, 20 mM 
CaC12), and fibrin formation was monitored optically. 
Statistics. Significant differences in body temperature, AST, 
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ALT, and MTP were calculated using a two-tailed t test. Significant 
differences in final survival were calculated using a chi-square t st, 
while significant differences in survivai t me (Kaphn Meier plots) 
were calculated using the Mantel modified Gehan's Generalized 
Wilcoxon Test. 
Results 
We investigated whether AGP had protective ffects against 
different lethal challenges with TNF or LPS. As shown in 
Table 1, bAGP could fully protect C3H/HeJ mice against a
lethal combination of mTNF and GaIN. In these mice, the 
LDt00 for mTNF in combination with GaIN is 0.1 /~g. 
Table 1. Protection by bAGP against he Lethal Effect of 
m TNF/GaIN Injection 
Pretreatment * 
bAGP bAGP TF BSA 
Challenge PBS (3 mg) (10 mg) (10 mg) (10 mg) 
0.01 /~g mTNF/ 
20 mg GalN 0/6 0/6 0/6 ND ND 
0.05/zg mTNF/ 
20 mg GalN 2/6 0/6 0/6 ND ND 
0.1 /~g mTNF/ 
20 mg GalN 6/6 0/6* 0/6t ND ND 
0.5 /~g mTNF/ 
20 mg GaiN 6/6 0/6* 0/6* 6/6 6/6 
1.0/~g mTNF/ 
20 mg GaIN 6/6 3/6 0/6* ND ND 
* C3H/HeJ mice were pretreated 2 hbefore the lethal challenge. Lethal- 
ity (number of th.~d mice vs. total number of mice) was monitored 24 h 
after the challenge (no further deaths occurred). 
* Significantly different (p<0.05) from PBS-pretreated mice (chi-square 
test). 
bAGP was capable of protecting against at least 5-10 such 
lethal doses. Not only bAGP protected against mTNF/GaiN 
lethality; human, rat, or mouse AGP also protected mice 
against mTNF/GaiN lethality (results not shown). Further- 
more, TF and BSA showed no protective activity. We used 
these two preparations (glycosylated and unglycosylated, 
respectively) as protein controls. 
As demonstrated in Fig. 1, statistically significant (p <0.001) 
protection was observed when bAGP was administered 2 or 
4 h, or even (p <0.05) 8 h before the lethal challenge. The 
animals of the latter group, however, finally all died. As can 
be seen in Fig. 1 A, after injection of mTNF/GaiN, the body 
temperature virtually drops to room temperature within 6 h. 
This is not the case in the animals pretreated with bAGP 2 
or 4 h before the challenge. 
When studying the minimal dose necessary to confer pro- 
tection against mTNF/GalN, we observed a very sharp dose/re- 
sponse relationship (Fig. 2): 3 mg bAGP still fully protected, 
whereas 1 mg was no longer effective. 
5-6 h after injection of mTNF/GalN, very high levels of 
ALT and AST were found in circulation as a result of mas- 
sive necrosis of the liver (Table 2). Also the enhanced ot- 
ting time (MPT) is a reflection of this necrosis. Mice pretreated 
with bAGP no longer exhibited these important metabolic 
changes. 
In Table 3 we demonstrate hat bAGP not only protects 
against TNF in GaiN-sensitized mice, but also in normal mice, 
for which the LDt00 (intravenous) of mTNF amounts to 
about 20/~g. hTNF, which only interacts with the routine 
receptor p55, is far less toxic than mTNF for mice (9); in 
the presence of GaiN, however, it becomes almost as toxic. 
But bAGP protected against hTNF/GaiN lethality (Table 3), 
and against the local Shwartzman reaction (results not shown). 
Furthermore, bAGP desensitizes towards apotentially ethal 
LPS injection in GaiN-sensitized mice. 
Discussion 
GaIN drastically sensitizes animals to the shock-inducing 
properties of LPS or TNF (10-12). Because GaIN is a specific 
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Figure 1. Time dependency of bAGP-induced protection against mTNF/GalN lethality. C3H/HeJ mice (n = 8) were treated with 3 mg bAGP at 
t = -8 h (~7), -4 h ([2]), -2 h (A), 0 h ( I)  or +2 h (A), except for the control (V). At t = 0 h, all mice were challenged with 0.5 ~g mTNF/20 
mg GAIN. (A) body temperature (~ after challenge. (B) Kaplan Meier plot of survival after challenge. 
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Figure 2. Dose dependency of bAGP-induced protection against mTNF/GalN lethality. C3H/HeJ mice (n = 10) were treated at - 2 h with 10 mg 
hAGP (m), 3 mg bAGP (&), 1 mg bAGP (e), 0.3 mg bAGP ( , )  or PBS (V). At t = 0 h, mice were challenged with 0.5/zg mTNF/20 mg GAIN. 
(A) body temperature (~ after challenge. (B) Kaplan Meier plot of survival after challenge. 
Table 2. Effect of bAGP on the Change in Metabolic Parameters 
after Injection of a Lethal Dose of raTNF/GalN 
Pretreatment* 
PBS bAGP (3 mg) 
AST* 10,240 + 640 600 • 400 
ALT* 10,480 • 400 360 • 240 
MPTS 1,500 • 139 164 • 16 
Body temperaturell 30.4 • 2.2 38,0 • 0.5 
Lethality I 8/8 0/8 
* C3H/HeJ mice were pretreated 2 h before the lethal challenge (0.5 #g 
mTFN/GalN). 
# Mean and SD (n = 8) in U/liter, 5 h after challenge; bAGP-pretreated 
mice were significantly different (p <0.05) from PBS-pretreated mice 
(t test). Basal levels were 93 • 31 U/liter (AST) and 97 _+ 22 U/liter 
(ALT). 
s Mean and SD (n =6) relative to untreated mice taken as 100, 5 h after 
challenge (100% value for control mice was 61 • 2 s); bAGP-pretreated 
mice were significantly different (p <0.05) from PBS-pretreated mice 
(t test). 
Mean and SD (n = 8) in ~ 6 h after challenge; bAGP-pretreated mice 
were significantly different (p <0.05) from PBS-pretreated mice (t test). 
82 Number of dead mice vs. total number of mice, 24 h after challenge 
(no further deaths occurred); bAGP-pretreated mice were significantly differ- 
ent (/, <0.05) from PBS-pretreated mice (chi-square test). 
hepatotoxin (itinhibits transcription and translation specifically 
in hepatocytes [13]) the liver is believed to play a central role 
in the defence against injury or systemic shock. 
In response to several cytokines and other factors released 
after injury, hepatocytes augment the expression of a set of 
proteins called the acute phase proteins (reviewed in 14). Some 
of these proteins, such as C-reactive protein, serum amyloid 
A and olt-antitrypsin, have been reported to protect animals 
from lethal endotoxemia or other inflammatory challenges 
(15-18). Protection against the lethal effects of TNF by acute 
phase proteins has, however, never been described. 
In this report we demonstrate that AGP significantly pro- 
tects mice from TNF- or LPS-induced lethality in GaIN- 
sensitized as well as in normal mice. bAGP protects against 
the enhanced plasma clotting time, the release of liver trans- 
aminases, the reduction of body temperature and mortality, 
when given at least 2 h before the challenge. The bAGP dose 
required in a bolus injection for protection is 3 mg, resulting 
in a serum concentration f about 1.5 mg/ml, and resembles 
the peak serum concentration f AGP during an acute phase 
response, namely ~,1.2 mg/ml (19, 20). 
Since the mechanism by which TNF leads to lethality in 
GaiN-sensitized animals is still largely unknown, the exact 
target of AGP remains unclear. However, Piguet et ai. (21) 
recently demonstrated that platelet aggregation a d adhesion 
to the endothelium plays a critical role in LPS/GalN toxicity. 
After aggregation, platelets may produce thromboxanes, pos- 
sible mediators of the toxic TNF activities in GaiN-sensitized 
animals (22). It is quite possible, therefore, that the potent 
platelet aggregation-inhibitory activity of AGP (23) provides 
the explanation for its protective capacity. 
AGP is also capable of augmenting the LPS-induced cyto- 
kine production of macrophages (24), and some cytokines 
(IL-1 and TNF) can desensitize against TNF/GalN-induced 
lethality (4, 25). However, optimal IL-l-induced protection 
requires that IL-1 is injected 12 h before TNF/GalN. Fur- 
thermore, we demonstrated that the liver mediates the IL-1 
effect. Hence, AGP may well be the IL-l-induced molecule 
in the liver responsible for desensitization (4). It may also 
be noted that we were unable to observe IL-1 or TNF in 
circulation in C3H/He J  mice after AGP injection (data not 
shown). Whether AGP is the only factor responsible for 
IL-1/TNF-induced esensitization will only become clear, 
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Table 3. bAGP Protects against TNF- or LPS-induced Lethality in Normal and GaiN-sensitized Mice 
Pretreatment* 
PBS bAGP (3 mg) 
Challenge Body temperature* LethalityS Body temperature* LethalityS 
0.5 #g mTNF/20 mg GaIN 
0.5 #g hTNF/20 mg GaIN 
20 #g mTNF 
0.1 #g LPS/20 mg GaIN 
30.4 _+ 2.2 8/8 38.0 +_ 0.511 0/81 
28.9 __ 2.5 8/8 36.9 _+ 0.8 I' 1/81 
27.9 _+ 3.0 5/5 36.4 _+ 0.8 II 0/51 
26.6 _+ 2.7 5/5 37.2 +_ 0.5 II 0/51 
* Mice, namely CsH/HeJ (TNF) or C57BI/CNB (LPS), were pretreated 2 h before the lethal challenge. 
* Mean and SD (~ measured 6 h (GAIN model) or 18 h (normal model) after the challenge; II means ignificantly different (p <0.05) from PBS- 
pretreated mice (t test). 
S Number of dead mice vs. total number of mice, 24 h (GAIN model) or 48 h (normal model) after challenge (no further deaths occurred); I means 
significantly different from PBS-pretreated mice (chi-square t st). 
when mice with a targeted isruption of the AGP genes will 
be available. 
It has been reported that AGP induces an IL-l-inhibiting 
factor in macrophages (26), most probably the IL-1 receptor 
antagonist (27). However, based on earlier studies with rlL-1 
receptor antagonist, we can conclude that this molecule is 
not sufficiently potent to explain the protection observed 
against TNF/GalN (28). 
Our findings provide evidence that AGP is part of a feed- 
back system induced in the liver and capable of significantly 
inhibiting the deleterious effects of TNF. 
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